MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
NUVB stock logo

NUVB

Nuvation Bio Inc.

$4.41
-0.1
 (-2.22%)
Exchange:  NYSE
Market Cap:  1.528B
Shares Outstanding:  80.992M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  David T. Hung
Full Time Employees:  273
Address: 
1500 Broadway
New York City
NY
10036
US
Website:  https://www.nuvationbio.com
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/11 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue07,87362,902
Gross Profit079554,460
EBITDA-75,580-566,915-190,945
Operating Income-99,822-592,627-213,064
Net Income-75,802-567,939-204,627

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets621,484540,626594,822
Total Liabilities16,361.99976,838289,106
Total Stockholders Equity605,122463,788305,716
Total Debt4,006.9998,91510,147
Cash and Cash Equivalents42,64935,723164,086

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-67,999-130,4130
Capital Expenditure-69-1620
Free Cash Flow-68,068-130,5750
Net Income-75,802-567,9390
Net Change in Cash-58,450-6,926128,363

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)670,192.747Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)879,246.440Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)766,365.800Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)134,038.549Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)175,849.287Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)153,273.159Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)144,625.536Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)205,911.654Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)172,819.746Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)1,903,778.941Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)2,497,626.040Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)2,176,972.338Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.510Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.600Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.420Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)2Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
?Enterprise Value
 (TTM)
: 
  ?EV/FCF
 (TTM)
: 
?Dividend Yield
 (TTM)
: 
  ?Payout Ratio
 (TTM)
: 
?ROE
 (TTM)
: 
  ?ROIC
 (TTM)
: 
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
?P/B
 (TTM)
: 
  ?Current Ratio
 (TTM)
: 

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate NUVB Intrinsic Value

Common questions about NUVB valuation

Is NUVB (NUVB) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for NUVB (NUVB) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is NUVB a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NUVB trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is NUVB’s P/E ratio?

You can see NUVB’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for NUVB?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is NUVB a good long-term investment?

Whether NUVB fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

NUVB

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-2.22
Chart data temporarily unavailable.
Daily snapshot

Trading Metrics:

Open: —   Previous Close: —
Day Low: —   Day High: —
Year Low:    Year High: 
Price Avg 50:    Price Avg 200: 
Volume:    Average Volume: 
Session data unavailable

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Nuvation Bio Inc. (NUVB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read